本帖最后由 老马 于 2013-3-13 13:43 编辑 " s5 Q4 I, x- G& U+ _6 Y7 [; z
% R$ y, I0 _0 s) l+ }, u4 A
健择（吉西他滨）+顺铂+阿瓦斯汀
% p: [* }6 P3 k" p) @; a Gemzar +Cisplatin + Avastin
$ W* D+ S( h2 i; g8 x" I5 `3 vhttp://annonc.oxfordjournals.org/content/21/9/1804.full
, h# w* J3 X4 HOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 8 h4 S# F' C x( }! d
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ( ?# h5 Q+ f! {3 |2 [7 u
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* H, \! Q% O9 X
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
3 S7 e& U7 ~. [4 s, x华为网盘附件：6 k% Q! t }/ z& U) U; c9 C9 A
【华为网盘】ava.JPG5 N. p; o7 H" n6 o z ^' Y5 ~
|
11011102001537 )
显身卡
